人類 DNA 疫苗市場 - 全球行業規模、份額、趨勢、競爭、機會、預測，2018-2028 年，按管理途徑、按應用、按最終用戶、按地區、競爭

由於人類癌症和傳染病的流行率不斷上升，全球人類 DNA 疫苗市場預計在 2024-2028 年預測期內將出現顯著增長。

根據全球癌症觀察站的數據，2020 年全球報告了大約 19,292,789 例新癌症病例。 乳腺癌、肺癌、結直腸癌、前列腺癌和胃癌是 2020 年報告的最常見癌症類型。 此外，越來越多的抗生素耐藥病原體預計將進一步推動人類 DNA 疫苗市場的增長。

各種疾病的患病率上升

在全球範圍內，癌症是導致死亡的主要原因。 根據世界衛生組織 (WHO) 的數據，在過去五年中，全世界報告了大約 50,550,287 例癌症病例。 這包括紫外線和電離輻射等物理致癌物、石棉等化學致癌物、煙草煙霧成分、酒精、黃曲霉毒素（一種食品污染物）、砷（一種飲用水污染物）、某些病毒和細菌。如寄生蟲感染和不健康的生活方式。 癌症已成為全球性的醫療保健挑戰。 開發抗癌療法的需求預計將支持全球人類 DNA 疫苗市場的增長。 同樣，艾滋病毒、人乳頭瘤病毒和肺結核等致命和潛在治療疾病的流行率不斷上升，預計將進一步推動全球人類 DNA 疫苗市場的增長。 截至 2021 年，全球約有 3840 萬人感染艾滋病毒。

抗生素耐藥病原體增加

抗生素耐藥性是對全球健康、糧食安全和發展的最大威脅之一。 流行病學模型描述了抗生素消耗與耐藥病原體之間的直接關係。 根據世界衛生組織 (WHO) 的數據，已在臨床開發中確定了 32 種抗生素，這些抗生素旨在對抗最優先的病原體。 在引起傳染病的被稱為“超級細菌”的多重耐藥菌中，有一些無法用抗生素等現有抗菌藥物治療。 此外，某些細菌對現有療法產生了耐藥性，因此需要開發能夠解決抗生素耐藥性問題的新型治療方案。 預計這將推動全球人類 DNA 疫苗市場的增長。

DNA 疫苗研發的增長

研發 (R&D) 實踐和活動的快速發展正在推動市場的增長，因為開發新的人源化疫苗以治療各種危及生命的疾病的需求不斷增長。我來了。 Clinicaltrials.gov 已在全球範圍內確定了 247 項處於不同開發階段的人類 DNA 疫苗臨床試驗。 這清楚地表明，世界各地正在進行大量研究和開發，以開髮用於治療各種疾病的人類 DNA 疫苗，這有助於全球人類 DNA 疫苗市場的增長。

近期發展

ZyCoV-D 是一種基於 DNA 質粒的 COVID-19 疫苗，由印度製藥公司 Cadira Healthcare 在生物技術產業研究援助委員會的支持下於 2021 年 8 月開發。 該疫苗已證明具有更高的安全性、有效性和免疫原性。 該疫苗無需注射即可注射到皮膚上，在臨床試驗中已被證明可提供 67% 的針對症狀性 COVID-19 的保護。 ZyCoV-D 是一種採用 PharmaJet 無針系統 Tropis 的 3 劑皮內疫苗，可顯著減少任何副作用並提高質量。 Zydus Cadila 已獲得印度藥品監管局（DCGI）對 ZyCoV-D 的緊急使用授權（EUA）批准。

可自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

• 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析。

內容

第 1 章概述

• 市場定義
• 市場範圍
  • 目標市場
  • 研究目標年份
  • 主要市場細分

第二章研究方法論

• 調查目的
• 基線調查方法
• 主要行業合作夥伴
• 主要協會和次要信息
• 調查方法
• 數據三角測量和驗證
• 假設和限制

第 3 章執行摘要

• 市場概覽
• 主要市場細分概述
• 主要市場參與者概覽
• 主要地區/國家概覽
• 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第 5 章人類 DNA 疫苗的全球市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按給藥途徑（肌內註射、皮下注射、皮內註射、其他（靜脈注射等））
  • 按應用（癌症、肺結核、HIV、其他（肝炎、流感等））
  • 按最終用戶（醫院/診所、生物技術/製藥公司、學術/研究機構、其他（門診手術中心、療養院等））
  • 按地區（北美、歐洲、亞太地區、南美、中東/非洲）
  • 按公司分類（2022 年）
• 市場地圖
  • 按給藥途徑
  • 通過使用
  • 最終用戶
  • 按地區

第6章北美人類DNA疫苗市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按給藥途徑
  • 通過使用
  • 最終用戶
  • 按國家
• 北美：國家/地區分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章歐洲人類 DNA 疫苗市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按給藥途徑
  • 通過使用
  • 最終用戶
  • 按國家
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 意大利
  • 西班牙

第8章亞太地區人類DNA疫苗市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按給藥途徑
  • 通過使用
  • 最終用戶
  • 按國家
• 亞太地區：國家/地區分析
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳大利亞

第9章南美人類DNA疫苗市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按給藥途徑
  • 通過使用
  • 最終用戶
  • 按國家
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章中東和非洲人類 DNA 疫苗市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按給藥途徑
  • 通過使用
  • 最終用戶
  • 按國家
• MEA：國家分析
  • 阿聯酋人類 DNA 疫苗
  • 沙特阿拉伯人類 DNA 疫苗
  • 南非人類 DNA 疫苗

第 11 章市場動態

• 司機
• 任務

第12章市場趨勢與發展

第13章臨床試驗分析

• 正在進行的臨床試驗
• 已完成臨床試驗
• 中止的臨床試驗
• 管道細分，按開發階段
• 管道細分，按狀態
• 按研究應用劃分的管道細分
• 按地區劃分的渠道細分
• 臨床試驗熱圖

第14章競爭格局

• BOEHRINGER INGELHEIM GmbH（Merial）
• ELI-LILLY（Novartis Animal Health）
• GeneOne Life Science
• GEOVAX LABS, INC
• Inovio Pharmaceuticals（VGX Animal Health）
• Genexine, Inc.
• VIATRIS INC.（Rottapharm Biotech）
• Takara Holdings（Takara Bio）
• ZOETIS INC.（Fort dodge Animal Health）
• Zydus Cadila

第 15 章戰略建議

Global Human DNA Vaccine Market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing to the growing prevalence of cancer and infectious diseases in humans. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide. Breast Cancer, Lung Cancer, Colorectum Cancer, Prostate Cancer, and Stomach Cancer were the most prevalent types of cancer cases reported in 2020. Additionally, an increase in the number of antibiotic-resistant pathogens is further expected to drive the growth of the human DNA Vaccine Market.

The growing prevalence of different diseases has significantly increased the demand for different types of vaccines. Additionally, growing research & development activities being initiated by various governments and pharmaceutical & biotechnology companies across the globe are further expected to create lucrative opportunities for the growth of the human DNA vaccine market in the coming years. In 2021, the research & development expenditure in the pharmaceutical industry across the globe was around USD238 billion.

Rise in Prevalence of Different Diseases

Globally, cancer is the leading cause of death. According to World Health Organization, around 50,550,287 cases of cancer prevalence have been reported worldwide in the last five years. This is due to the physical carcinogens, such as ultraviolet and ionizing radiation; chemical carcinogens, such as asbestos, components of tobacco smoke, alcohol, aflatoxin (a food contaminant), and arsenic (a drinking water contaminant) and biological carcinogens, such as infections from certain viruses, bacteria, or parasites as well as unhealthy lifestyle. Cancer has become a global healthcare concern. The need to develop therapies for cancer is expected to support the growth of global human DNA vaccine market. Similarly, the increasing prevalence of diseases such as HIV, Human Papillomavirus, and Tuberculosis, which are deadly and require a potential treatment, is further expected to drive the growth of global human DNA vaccine market. As of 2021, globally, around 38.4 million people were living with HIV.

Increase in Number of Antibiotics Resistant Pathogens

Antibiotic resistance is one of the biggest threats to global health, food security, and development. The epidemiological models describe a direct relationship between antibiotic consumption and resistant pathogen. According to World Health Organization, 32 antibiotics were identified in clinical development, which addressed the top priority pathogens. Some multi and resistant bacteria called "superbugs" that cause infections are not treatable with existing antimicrobial medicines such as antibiotics. Also, certain bacteria have developed resistance to existing treatment options, thereby creating a need to develop novel therapeutic solutions which can address the issue of antibiotic resistance. This, in turn, is expected to fuel the growth of Global Human DNA Vaccine Market.

Growth in R&D for DNA Vaccine

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need to develop novel human vaccines for the treatment of different life-threatening diseases. According to Clinicaltrials.gov, 247 clinical trials are in different phases of development across the globe for Human DNA vaccines. This clearly indicates that a lot of R&D is being done across the globe for developing human DNA vaccines for the treatment of different diseases, thereby supporting the growth of the global human DNA vaccine market.

Recent Developments

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council in August 2021. This vaccine illustrated higher safety, efficacy, and immunogenicity. The vaccine is administered into the skin without an injection and has been found to be 67% protective against symptomatic COVID-19 in clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet needle-free system, Tropis, which can significantly reduce any side effects and improve quality. Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D.

Market Segmentation

Global Human DNA Vaccine Market can be segmented based on the mode of administration, application, end user, and region. Based on the mode of administration, the market can be categorized into intramuscular, subcutaneous, intradermal, and others. Based on application, the market can be fragmented into oncology, tuberculosis, HIV, human papillomavirus, and others. Based on end users, the market can be grouped into hospitals & clinics, biotechnology & pharmaceutical companies, academic & research institutions, and others.

Company Profiles

BOEHRINGER INGELHEIM GmbH (Merial), ELI-LILLY (Novartis Animal Health), Gene One Life Science, GEOVAX LABS, INC, Inovio Pharmaceuticals (VGX Animal Health), Genexine, Inc., VIATRIS INC. (Rottapharm Biotech), Takara Holdings (Takara Bio), ZOETIS INC. (Fort Dodge Animal Health), Zydus Lifesciences Limited are some of the key players operating in the global Human DNA Vaccine market.

Report Scope

In this report, Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Human DNA Vaccine Market, By Mode of Administration:

• Intramuscular
• Subcutaneous
• Intradermal
• Others

Human DNA Vaccine Market, By Application:

• Oncology
• Tuberculosis
• HIV
• Human Papillomavirus
• Others

Human DNA Vaccine Market, By End User:

• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Human DNA Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Human DNA Vaccine market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human DNA Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others include (Intravenous, etc.)
  • 5.2.2. By Application (Oncology, Tuberculosis, HIV, Others include (Hepatitis, Influenza, etc.)
  • 5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others include (Ambulatory surgical centers, Nursing homes, etc.)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle-East and Africa)
  • 5.2.5. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Route of Administration
  • 5.3.2. By Application
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Human DNA Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human DNA Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Human DNA Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Human DNA Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Human DNA Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human DNA Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Human DNA Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Human DNA Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Human DNA Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1.1. By Route of Administration
      • 7.3.4.2.1.2. By Application
      • 7.3.4.2.1.3. By End User
  • 7.3.5. Spain Human DNA Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Human DNA Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human DNA Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. Japan Human DNA Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. India Human DNA Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Human DNA Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Human DNA Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Human DNA Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human DNA Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Human DNA Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Human DNA Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Human DNA Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Human DNA Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. South Africa Human DNA Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Application
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (In Case of Listed Companies)
• 14.5. Key Personnel
  • 14.5.1. BOEHRINGER INGELHEIM GmbH (Merial)
  • 14.5.2. ELI-LILLY (Novartis Animal Health)
  • 14.5.3. GeneOne Life Science
  • 14.5.4. GEOVAX LABS, INC
  • 14.5.5. Inovio Pharmaceuticals (VGX Animal Health)
  • 14.5.6. Genexine, Inc.
  • 14.5.7. VIATRIS INC. (Rottapharm Biotech)
  • 14.5.8. Takara Holdings (Takara Bio)
  • 14.5.9. ZOETIS INC. (Fort dodge Animal Health)
  • 14.5.10. Zydus Cadila

15. Strategic Recommendations